ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > perfect excuse

<< Previous

Bullboard Posts

Next >>

Comment by azzymaaon Feb 24, 2022 4:48pm

106 Views

Post# 34459637

RE:perfect excuse

Sorry to hear that kalman, hopefully you did not invest too much. I don't have much invested so I really don't care too much. i'm more into bluechip long term stocks but got interested in biogen and promis last year and was dumb enough to buy biogen at a high. I'll stick around until years end and sell and buy royal bank or enbridge or might end up with zero lol

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?